Drug therapy in internal medicine

被引：0
|
作者：
Rahn, KH
机构：
来源：
INTERNIST | 2000年 / 41卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [41] THERAPY OF SELECTED CARDIAC-ARRHYTHMIAS IN INTERNAL MEDICINE
    GERTSCH, M
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1978, 108 (15) : 564 - 572
  • [42] PROGNOSIS AND THERAPY IN INTERNAL MEDICINE - SPANISH - ARASA,F
    PENDE, N
    FOLIA HUMANISTICA, 1971, 9 (105) : 758 - 759
  • [43] Oxygen therapy: a clinical audit in an Internal Medicine Department
    Nunes, S.
    Maia, J.
    Ferreira, J. P.
    Neves, J.
    Marques, I.
    REVISTA PORTUGUESA DE PNEUMOLOGIA, 2015, 21 (02) : 101 - 103
  • [44] What is confirmed in Kneipp therapy? The perspective of internal medicine
    Ehnert, Lutz
    Geiser, Caroline
    INNERE MEDIZIN, 2022, 63 (12): : 1229 - 1236
  • [45] Review: Drug therapy in Chinese traditional medicine
    Cheng, JT
    JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (05): : 445 - 450
  • [46] The beginnings of, drug therapy: Ancient Mesopotamian medicine
    Borchardt, JK
    DRUG NEWS & PERSPECTIVES, 2002, 15 (03) : 187 - 192
  • [47] The beginnings of drug therapy: Ancient Egyptian medicine
    Borchardt, JK
    DRUG NEWS & PERSPECTIVES, 1999, 12 (02) : 123 - 127
  • [48] Personalized vascular medicine: Individualizing drug therapy
    deGoma, Emil M.
    Rivera, Giovanni
    Lilly, Scott M.
    Usman, M. Haris U.
    Mohler, Emile R., III
    VASCULAR MEDICINE, 2011, 16 (05) : 391 - 404
  • [49] Readmissions and adverse drug reactions in internal medicine:: the economic impact
    Dormann, H
    Neubert, A
    Criegee-Rieck, M
    Egger, T
    Radespiel-Tröger, M
    Azaz-Livshits, T
    Levy, M
    Brune, K
    Hahn, EG
    JOURNAL OF INTERNAL MEDICINE, 2004, 255 (06) : 653 - 663
  • [50] Adverse drug reactions as a cause for admissions to a department of internal medicine
    Mjörndal, T
    Boman, MD
    Hägg, S
    Bäckström, M
    Wiholm, BE
    Wahlin, A
    Dahlqvist, R
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (01) : 65 - 72
12345